Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Exicure logo — A pioneer in gene regulatory and immunotherapeutic drugs uti...

Exicure

A pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology

Founded 2011 United States Chicago, United States 6 employees Post-IPO Equity Total: $110.85M Biotechnology, Health and Wellness +1

General Information

Company Name Exicure
Founded Year 2011
Location United States Chicago, United States
Employees 6
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Exicure. To contact Exicure, visit exicuretx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Exicure

Exicure, formerly known as AuraSense Therapeutics, is pioneering a new class of immunomodulatory and gene silencing drugs targeting validated medical conditions. Utilizing a 3-dimensional, spherical nucleic acid (SNA™) structure, the company enhances the efficacy of nucleic acid therapeutics across various organs. Its primary programs focus on a range of diseases from inflammatory disorders to oncology. SNA constructs address one of the most challenging hurdles in nucleic acid therapeutics: achieving safe and effective delivery into cells and tissues. These constructs demonstrate exceptional transfection efficiency across numerous cell and tissue types, including the skin, without the need for carriers or transfection agents. Additionally, SNAs serve as powerful immunotherapeutic agents for treating cancer and infectious diseases. Founded in 2009, Exicure operates in the Biotechnology industry. The company recently secured a $5.40M Post-IPO Equity investment from CBI USA on 26 September 2022.

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $5.40M 1
CBI USA
26 Sep 2022
Post IPO Equity $11.50M -
14 Dec 2021
Venture Round $22.00M -
31 Aug 2018
Venture Round $11.20M 9
Hercules Capital Innovation Endeavors HongTao Capital
Hercules Capital, Innovation Endeavors +7
06 Nov 2017
Venture Round $20.00M 10
AbbVie Ventures Katalyst Securities
AbbVie Ventures, Katalyst Securities +8
27 Sep 2017
Series C Undisclosed 1
Acequia Capital (AceCap)
01 Jan 2016
Venture Round $14.80M 2
Tempus, Liz Lefkofsky
21 Oct 2015
Series C $4.50M -
05 Feb 2015
Series C $13.60M 4
Patrick Ryan, Craig Mundie +2
17 Jun 2014
Series B Undisclosed 1
AbbVie Ventures
AbbVie Ventures
31 Jul 2013

View All 12 Funding Rounds

FAQ About Exicure

A pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology
Exicure was founded in 2011.
Exicure is headquartered in Chicago, United States.
Exicure operates in Biotechnology, Health and Wellness and Life Sciences.
Exicure has approximately 6 employees.
Exicure has completed 12 funding rounds, raising a total of $110.85M. The latest funding stage is Post-IPO Equity.

We're actively collecting intelligence on Exicure.

Source: BounceWatch company record for Exicure, https://bouncewatch.com/company/exicure, updated 28 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes